OA12650A - Crystals including a malic acid salt of N-Ä2-(diethylamino)ethylÜ-5-Ä(5-fluoro-2-oxo-3H-indole-3-ylidene)methylÜ-2,4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof. - Google Patents

Crystals including a malic acid salt of N-Ä2-(diethylamino)ethylÜ-5-Ä(5-fluoro-2-oxo-3H-indole-3-ylidene)methylÜ-2,4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof. Download PDF

Info

Publication number
OA12650A
OA12650A OA1200400044A OA1200400044A OA12650A OA 12650 A OA12650 A OA 12650A OA 1200400044 A OA1200400044 A OA 1200400044A OA 1200400044 A OA1200400044 A OA 1200400044A OA 12650 A OA12650 A OA 12650A
Authority
OA
OAPI
Prior art keywords
crystal
malic acid
diethylamino
oxo
dimethyl
Prior art date
Application number
OA1200400044A
Other languages
English (en)
Inventor
Thomas J Fleck
Michael Hawley
Mark T Maloney
Stephen P Prescott
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12650(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of OA12650A publication Critical patent/OA12650A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
OA1200400044A 2001-08-15 2002-08-13 Crystals including a malic acid salt of N-Ä2-(diethylamino)ethylÜ-5-Ä(5-fluoro-2-oxo-3H-indole-3-ylidene)methylÜ-2,4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof. OA12650A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15

Publications (1)

Publication Number Publication Date
OA12650A true OA12650A (en) 2006-06-19

Family

ID=23211067

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400044A OA12650A (en) 2001-08-15 2002-08-13 Crystals including a malic acid salt of N-Ä2-(diethylamino)ethylÜ-5-Ä(5-fluoro-2-oxo-3H-indole-3-ylidene)methylÜ-2,4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof.

Country Status (43)

Country Link
US (2) US20030069298A1 (hr)
EP (3) EP1419151B1 (hr)
JP (1) JP4159988B2 (hr)
KR (1) KR100639281B1 (hr)
CN (2) CN100364991C (hr)
AP (1) AP1660A (hr)
AR (1) AR036261A1 (hr)
AU (1) AU2002324684B2 (hr)
BG (1) BG108553A (hr)
BR (1) BR0211612A (hr)
CA (1) CA2455050C (hr)
CO (1) CO5550431A2 (hr)
CU (1) CU23713B7 (hr)
CY (1) CY1121552T1 (hr)
CZ (1) CZ2004196A3 (hr)
DK (2) DK1419151T3 (hr)
EA (1) EA006445B9 (hr)
EC (1) ECSP044975A (hr)
ES (3) ES2623094T3 (hr)
GE (1) GEP20063777B (hr)
HK (2) HK1066542A1 (hr)
HR (1) HRP20040112B1 (hr)
HU (1) HU229206B1 (hr)
IL (1) IL160097A0 (hr)
IS (1) IS7147A (hr)
MA (1) MA27058A1 (hr)
ME (1) ME00414B (hr)
MX (1) MXPA04001452A (hr)
MY (1) MY139383A (hr)
NO (1) NO326508B1 (hr)
NZ (1) NZ531232A (hr)
OA (1) OA12650A (hr)
PL (1) PL216524B1 (hr)
PT (2) PT3168218T (hr)
RS (1) RS53251B (hr)
SI (2) SI3168218T1 (hr)
SK (1) SK902004A3 (hr)
TN (1) TNSN04028A1 (hr)
TR (1) TR201900509T4 (hr)
TW (1) TWI269796B (hr)
UA (1) UA76483C2 (hr)
WO (1) WO2003016305A1 (hr)
ZA (1) ZA200400706B (hr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201900509T4 (tr) 2001-08-15 2019-02-21 Pharmacia & Upjohn Co Llc Bir ilaç olarak kullanılmaya yönelik n-[2-(dietilamino)etil]-5-[(5-floro-1,2-dihidro-2-okso-3h-indol-3-iliden)metil]-2,4-dimetil-1h-pirol-3-karboksamidin l-malik asit tuzunu içeren bir kristal.
HN2003000272A (es) * 2002-09-10 2008-07-29 Pharmacia Italia Spa Formulaciones que comprenden un compuesto de indolinona
EP1670785B1 (en) * 2003-10-02 2010-07-07 Pharmacia & Upjohn Company LLC Salts and polymorphs of a pyrrole-substituted indolinone compound
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
JP4922163B2 (ja) * 2004-07-22 2012-04-25 イーライ リリー アンド カンパニー (s)−6−(4−(2−((3−(9h−カルバゾール−4−イルオキシ)−2−ヒドロキシプロピル)アミノ)−2−メチルプロピル)フェノキシ)−3−ピリジンカルボキサミドヘミコハク酸塩の結晶質の不定比水和物
KR20070119745A (ko) * 2005-05-12 2007-12-20 화이자 인코포레이티드 수니티닙 말레이트를 사용하는 항암 병행 요법
AU2006293644B2 (en) 2005-09-19 2012-05-31 Zoetis Services Llc Solid salt forms of a pyrrole substituted 2-indolinone
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
CA2699305A1 (en) 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
EP2229380A1 (en) * 2007-12-12 2010-09-22 Medichem, S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
CA2715657A1 (en) * 2008-02-21 2009-08-27 Generics (Uk) Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
ES2391501T3 (es) * 2008-03-31 2012-11-27 Teva Pharmaceutical Industries Ltd. Procedimientos para preparar sunitinib y sales del mismo
WO2009128083A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
KR101375156B1 (ko) 2008-05-23 2014-03-18 쟝수 치아타이 티안큉 파마수티컬 주식회사 디하이드로인돌리논 유도체들
AR072117A1 (es) * 2008-06-13 2010-08-04 Medichem Sa Procedimiento para preparar una sal de malato 3-pirrol sustituido 2-indolinona, intermediario de sintesis y una composicion farmaceutica que la comprende.
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
JP2011527330A (ja) * 2008-07-10 2011-10-27 ジェネリクス・(ユーケー)・リミテッド スニチニブリンゴ酸塩の結晶形の調製方法
CN102164913A (zh) * 2008-07-24 2011-08-24 麦迪凯姆股份公司 一种3-吡咯替代的2-吲哚酮苹果酸盐的结晶体形式
KR20110036588A (ko) 2008-07-24 2011-04-07 테바 파마슈티컬 인더스트리즈 리미티드 수니티닙 아세테이트 및 이의 다형을 통한 수니티닙 말레이트의 제조 방법
EP2318393A1 (en) * 2008-08-25 2011-05-11 Generics [UK] Limited Novel polymorphs of sunitinib and processes for their preparation
AU2009286520A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Crystalline form of sunitinib and processes for its preparation
EP2350056A1 (en) * 2008-10-10 2011-08-03 Medichem, S.A. Process for preparing a 3-pyrrole subsituted 2-indolinone malate salt
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2373643A4 (en) * 2009-01-02 2013-08-07 Hetero Research Foundation NEW SUNITINIB MALATE POLYMORPHS
PL2387563T5 (pl) 2009-01-16 2023-03-13 Exelixis, Inc. Sól jabłczanowa N-(4-{[6,7-bis(metyloksy)chinolin-4-ylo]oksy}fenylo-N′-(4-fluorofenylo)cykloproano-1,1-dikarboksyamidu oraz jej krystaliczne postaci do leczenia raka
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
EP2477978A1 (en) 2009-09-16 2012-07-25 Ranbaxy Laboratories Limited Salts of sunitinib
WO2011058521A2 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
WO2011061613A1 (en) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib
WO2011092664A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
US20130123511A1 (en) 2010-03-04 2013-05-16 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
WO2011114246A1 (en) 2010-03-18 2011-09-22 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
EP2699598B1 (en) 2011-04-19 2019-03-06 Pfizer Inc Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
EP2828251B1 (en) 2012-03-23 2018-10-31 Laurus Labs Limited An improved process for the preparation of sunitinib and its acid addition salts thereof
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
US9278955B2 (en) 2013-10-18 2016-03-08 Sun Pharmaceutical Industries Limited Ascorbic acid salt of sunitinib
EP3524262A1 (en) 2013-11-01 2019-08-14 Pfizer Inc Vectors for expression of prostate-associated antigens
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技(北京)有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
EP3955952A4 (en) * 2019-04-18 2023-01-25 Meter Health, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY ARRHYTHMIA
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9106978A (pt) 1990-10-15 1993-09-28 Pfizer Derivados de indol
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
CA2097208C (en) 1992-06-05 2005-02-08 Raymond Baker The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
ATE202109T1 (de) 1993-03-12 2001-06-15 Upjohn Co Kristallines ceftiofur (freie säure)
US6329364B1 (en) * 1994-08-31 2001-12-11 Eli Lilly And Company Crystalline form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de) * 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US6066647A (en) * 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
NZ334132A (en) 1996-08-14 2000-06-23 G Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide
KR100530601B1 (ko) * 1996-12-25 2005-11-23 니폰 가야꾸 가부시끼가이샤 시스플라틴 미분말 및 그의 제조방법
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
CN102020617B (zh) * 1998-06-19 2019-04-23 帝人制药株式会社 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸的多晶型体及其制备方法
WO2000035908A1 (en) * 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
ATE514676T1 (de) * 1999-11-24 2011-07-15 Sugen Inc Ionisierbare indolinon derivate und deren verwendung als ptk liganden
ATE369359T1 (de) * 2000-02-15 2007-08-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
US6316672B1 (en) * 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
TR201900509T4 (tr) 2001-08-15 2019-02-21 Pharmacia & Upjohn Co Llc Bir ilaç olarak kullanılmaya yönelik n-[2-(dietilamino)etil]-5-[(5-floro-1,2-dihidro-2-okso-3h-indol-3-iliden)metil]-2,4-dimetil-1h-pirol-3-karboksamidin l-malik asit tuzunu içeren bir kristal.
CA2715657A1 (en) 2008-02-21 2009-08-27 Generics (Uk) Limited Novel polymorphs and processes for their preparation
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Also Published As

Publication number Publication date
EP3168218A1 (en) 2017-05-17
TWI269796B (en) 2007-01-01
CN100364991C (zh) 2008-01-30
UA76483C2 (en) 2006-08-15
RS53251B (sr) 2014-08-29
PL216524B1 (pl) 2014-04-30
CN100439360C (zh) 2008-12-03
RS10304A (en) 2007-02-05
NO326508B1 (no) 2008-12-15
NZ531232A (en) 2004-11-26
EP3168218B1 (en) 2018-11-14
PL368317A1 (en) 2005-03-21
CY1121552T1 (el) 2020-05-29
JP4159988B2 (ja) 2008-10-01
EP2332934A1 (en) 2011-06-15
PT3168218T (pt) 2019-01-11
CN1789264A (zh) 2006-06-21
ES2623094T3 (es) 2017-07-10
SK902004A3 (sk) 2005-03-04
AU2002324684B2 (en) 2006-10-05
CA2455050C (en) 2007-02-20
US20070191458A1 (en) 2007-08-16
TNSN04028A1 (fr) 2006-06-01
MA27058A1 (fr) 2004-12-20
MY139383A (en) 2009-09-30
ZA200400706B (en) 2005-05-25
SI3168218T1 (sl) 2019-05-31
EP2332934B1 (en) 2017-03-01
NO20041054L (no) 2004-03-12
US20030069298A1 (en) 2003-04-10
HUP0700036A2 (en) 2008-10-28
KR20040030074A (ko) 2004-04-08
IL160097A0 (en) 2004-06-20
CU23713B7 (es) 2011-10-05
HRP20040112B1 (hr) 2012-03-31
EA006445B1 (ru) 2005-12-29
DK1419151T3 (da) 2014-03-31
SI1419151T1 (sl) 2014-04-30
TR201900509T4 (tr) 2019-02-21
DK3168218T3 (en) 2019-01-14
MXPA04001452A (es) 2004-05-20
EP1419151B1 (en) 2014-02-26
EA006445B9 (ru) 2017-02-28
CO5550431A2 (es) 2005-08-31
PT1419151E (pt) 2014-03-27
BR0211612A (pt) 2004-08-24
ES2705063T3 (es) 2019-03-21
ECSP044975A (es) 2004-03-23
IS7147A (is) 2004-02-10
ES2453164T3 (es) 2014-04-04
HU229206B1 (en) 2013-09-30
HRP20040112A2 (en) 2004-06-30
CU20040029A7 (es) 2008-03-14
BG108553A (bg) 2005-04-30
GEP20063777B (en) 2006-03-27
ME00414B (me) 2011-10-10
US7435832B2 (en) 2008-10-14
CA2455050A1 (en) 2003-02-27
EA200400183A1 (ru) 2004-08-26
AP2004002976A0 (en) 2004-03-31
AR036261A1 (es) 2004-08-25
HK1088008A1 (en) 2006-10-27
AP1660A (en) 2006-09-09
WO2003016305A1 (en) 2003-02-27
CN1543462A (zh) 2004-11-03
HK1066542A1 (en) 2005-03-24
EP1419151A1 (en) 2004-05-19
CZ2004196A3 (cs) 2005-01-12
JP2005503386A (ja) 2005-02-03
KR100639281B1 (ko) 2006-10-31

Similar Documents

Publication Publication Date Title
OA12650A (en) Crystals including a malic acid salt of N-Ä2-(diethylamino)ethylÜ-5-Ä(5-fluoro-2-oxo-3H-indole-3-ylidene)methylÜ-2,4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof.
AU2002324684A1 (en) Crystals including a malic acid salt of N-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3H-indole-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
US20210261556A1 (en) Short-acting benzodiazepine salts and their polymorphic forms
CA2493310C (en) 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
ES2326654T3 (es) Metanosulfonato del ester etilico del acido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propionico de la formula a y su uso como medicamento.
TW200838512A (en) Crystalline forms of a thiazolidinedione compound and manufacturing methods thereof
WO2018153632A1 (en) Crystalline forms of valbenazine salts
WO2004092160A1 (ja) 臭化物及びその結晶
US9290479B2 (en) Solid salt forms of a pyrrole substituted 2-indolinone
MXPA04010845A (es) Formas cristalinas novedosas de ondansetron, procesos para su preparacion, composiciones farmaceuticas que contienen las formas novedosas y metodos para tratar las nauseas utilizando las mismas.
US20020193386A1 (en) Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
US20030191141A1 (en) Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
US20030191140A1 (en) Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof